Similarly, AKT inhibitor was used in lung cancer with KEAP1 mutation through interaction of cellular antioxidant pathway (Fan et al., 2023) and could assist to kill tumor cell (Dai et al., 2013). The gene discussed is KEAP1; the disease is lung carcinoma.